CL2017002059A1 - Compuestos 4- sustitutos de benzoxaborol y uso de los mismos - Google Patents

Compuestos 4- sustitutos de benzoxaborol y uso de los mismos

Info

Publication number
CL2017002059A1
CL2017002059A1 CL2017002059A CL2017002059A CL2017002059A1 CL 2017002059 A1 CL2017002059 A1 CL 2017002059A1 CL 2017002059 A CL2017002059 A CL 2017002059A CL 2017002059 A CL2017002059 A CL 2017002059A CL 2017002059 A1 CL2017002059 A1 CL 2017002059A1
Authority
CL
Chile
Prior art keywords
compounds
ch2c
benzoxaborol
substitutes
h2ch3
Prior art date
Application number
CL2017002059A
Other languages
English (en)
Inventor
Jacob J Plattner
Xianfeng Li
David Barros-Aguirre
Ilaria Giordano
Carlos Alemparte-Gallardo
M R K Alley (Dickon)
Vincent Hernandez
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Anacor Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55409879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017002059(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd, Anacor Pharmaceuticals Inc filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of CL2017002059A1 publication Critical patent/CL2017002059A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/04Esters of boric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

<p>Se proporcionan benzoxaboroles sustituidos cuya estructura comprende la fórmula III: (Fórmula III) en donde R3 se selecciona a partir de –CH3 , –CH2CH3 , –CH2 =CH2 ,       –CH2C H2CH3 , –CH(CH3 ) 2 , – CH2C H2 =CH2 y ciclopropilo, R1 y R2 se seleccionan cada uno independientemente a partir de H,  - CH3 ,-C H2C H3 , –CH2C H2CH3 y –CH(CH3 ) 2 ; composiciones que contienen estos compuestos, su uso en terapia, incluyendo su uso como agentes anti-micobacterianos, por ejemplo, en el tratamiento de una infección micobacteriana en un mamífero, y los métodos para la preparación de estos compuestos.</p>
CL2017002059A 2015-02-12 2017-08-11 Compuestos 4- sustitutos de benzoxaborol y uso de los mismos CL2017002059A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15382056 2015-02-12
EP15382055 2015-02-12
EP15382054 2015-02-12

Publications (1)

Publication Number Publication Date
CL2017002059A1 true CL2017002059A1 (es) 2018-03-16

Family

ID=55409879

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2017002060A CL2017002060A1 (es) 2015-02-12 2017-08-11 Compuestos de benzoxaborol y usos de los mismos
CL2017002059A CL2017002059A1 (es) 2015-02-12 2017-08-11 Compuestos 4- sustitutos de benzoxaborol y uso de los mismos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2017002060A CL2017002060A1 (es) 2015-02-12 2017-08-11 Compuestos de benzoxaborol y usos de los mismos

Country Status (36)

Country Link
US (3) US20180037595A1 (es)
EP (2) EP3256479B1 (es)
JP (2) JP2018506540A (es)
KR (2) KR20170117156A (es)
CN (2) CN107531730B (es)
AU (3) AU2016217508A1 (es)
BR (2) BR112017017213A2 (es)
CA (2) CA2976308A1 (es)
CL (2) CL2017002060A1 (es)
CO (2) CO2017008809A2 (es)
CR (2) CR20170372A (es)
CY (1) CY1123687T1 (es)
DK (1) DK3256479T3 (es)
DO (2) DOP2017000188A (es)
EA (2) EA201791667A1 (es)
ES (1) ES2821951T3 (es)
HR (1) HRP20201597T1 (es)
HU (1) HUE051113T2 (es)
IL (2) IL253864B (es)
LT (1) LT3256479T (es)
MA (2) MA41495A (es)
MX (2) MX379057B (es)
MY (1) MY194004A (es)
NZ (1) NZ734379A (es)
PE (2) PE20171432A1 (es)
PH (2) PH12017501427A1 (es)
PL (1) PL3256479T3 (es)
PT (1) PT3256479T (es)
RS (1) RS60885B1 (es)
SG (2) SG11201706510YA (es)
SI (1) SI3256479T1 (es)
SM (1) SMT202000565T1 (es)
TW (2) TW201702250A (es)
UA (1) UA120527C2 (es)
WO (2) WO2016128949A1 (es)
ZA (1) ZA201705456B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105492388B (zh) * 2013-08-09 2018-12-21 葛兰素史克知识产权第二有限公司 三环苯并氧杂硼杂环戊烯化合物及其用途
BR112019023322B1 (pt) * 2017-05-08 2023-11-14 Glaxosmithkline Intellectual Property Development Limited Uso do sanfetrinem, sanfetrinem sódico ou sanfetrinem cilexetila para a produção de um medicamento para o tratamento de tuberculose e combinação de sanfetrinem
BR112020010927A2 (pt) 2017-11-30 2020-12-01 Boragen, Inc. compostos de benzoxaborol e formulações dos mesmos
WO2020041200A1 (en) 2018-08-18 2020-02-27 Boragen Inc. Solid forms of substituted benzoxaborole and compositions thereof
CN110441344B (zh) * 2019-06-25 2020-09-29 北京大学 一种基于固体核磁共振技术检测rna结构的方法
CN119233977B (zh) * 2022-06-23 2026-03-17 上海盟科药业股份有限公司 硼化合物的前药及其在治疗细菌感染中的用途
CN119233823A (zh) * 2022-06-23 2024-12-31 上海盟科药业股份有限公司 硼化合物治疗非结核分枝杆菌感染的方法和用途及用于治疗相同疾病的药物组合物
KR20240150582A (ko) 2023-04-08 2024-10-15 김태서 맥세이프 배터리팩을 포함한 아이폰 케이스

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9411587D0 (en) * 1994-06-09 1994-08-03 Zeneca Ltd Compound, composition and use
AU4967997A (en) 1996-12-02 1998-06-29 Chisso Corporation Optically active nitro alcohol derivatives, optically active amino alcohol derivates, and process for preparing the same
CA2507908A1 (en) 2002-12-02 2004-06-17 Solvias Ag Catalytic hydrogeneration of carbon-heteroatom double bonds
JP5038912B2 (ja) 2005-02-16 2012-10-03 アナコール ファーマシューティカルズ,インコーポレイテッド ホウ素含有小分子
US7767657B2 (en) 2005-02-16 2010-08-03 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2006096131A1 (en) 2005-03-08 2006-09-14 Agency For Science, Technology And Research Chiral bisoxazoline catalysts
TWM325238U (en) * 2006-12-29 2008-01-11 Universal Scient Ind Co Ltd Voltage regulator and voltage regulating system
KR100848491B1 (ko) 2007-01-16 2008-07-28 영진약품공업주식회사 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법
JO3396B1 (ar) 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
MX2011006334A (es) 2008-12-17 2011-09-22 Anacor Pharmaceuticals Inc Polimorfos de (s)-3-amino-metil-7-(3-hidroxi-propoxi)-3h-benzo-[c] [1,2]-oxaborol-1-ol.
WO2011037731A1 (en) * 2009-09-25 2011-03-31 Anacor Pharmaceuticals, Inc. Boron containing small molecules
JP5603998B2 (ja) * 2010-04-07 2014-10-08 グラクソスミスクライン エルエルシー ベンゾオキサボロールの調製方法
SG10201507032YA (en) 2010-09-07 2015-10-29 Anacor Pharmaceuticals Inc Benzoxaborole derivatives for treating bacterial infections
US8530452B2 (en) * 2011-12-22 2013-09-10 Micurx Pharmaceuticals, Inc. Tricyclic boron compounds for antimicrobial therapy
CN102739587B (zh) 2012-06-16 2014-05-21 天地融科技股份有限公司 音频数据传输方法
KR101636431B1 (ko) 2013-07-30 2016-07-05 동아에스티 주식회사 트리사이클릭 벤즈옥사보롤 화합물, 이의 제조방법 및 용도
CN105492388B (zh) 2013-08-09 2018-12-21 葛兰素史克知识产权第二有限公司 三环苯并氧杂硼杂环戊烯化合物及其用途

Also Published As

Publication number Publication date
IL253864B (en) 2021-07-29
BR112017017213A2 (pt) 2018-04-03
US20180044353A1 (en) 2018-02-15
KR20170117158A (ko) 2017-10-20
IL253864A0 (en) 2017-09-28
IL253865A0 (en) 2017-10-31
TW201643173A (zh) 2016-12-16
DOP2017000188A (es) 2017-09-15
LT3256479T (lt) 2020-12-28
CN107548398A (zh) 2018-01-05
AU2016217507A1 (en) 2017-09-28
PT3256479T (pt) 2020-10-22
SI3256479T1 (sl) 2020-11-30
JP2018506538A (ja) 2018-03-08
PE20171348A1 (es) 2017-09-13
MA41495A (fr) 2017-12-19
TW201702250A (zh) 2017-01-16
SMT202000565T1 (it) 2020-11-10
ZA201705456B (en) 2019-10-30
CO2017008809A2 (es) 2017-11-10
DOP2017000189A (es) 2018-02-15
PE20171432A1 (es) 2017-09-26
US20180037595A1 (en) 2018-02-08
JP6771472B2 (ja) 2020-10-21
CN107531730B (zh) 2020-08-07
AU2016217508A1 (en) 2017-09-28
PL3256479T3 (pl) 2021-06-14
MA41494A (fr) 2017-12-19
AU2016217507B2 (en) 2019-03-14
CA2976308A1 (en) 2016-08-18
CL2017002060A1 (es) 2018-03-16
US10774096B2 (en) 2020-09-15
CR20170372A (es) 2017-10-19
CO2017008816A2 (es) 2017-11-10
BR112017017211A2 (pt) 2018-04-03
MA41494B1 (fr) 2020-10-28
WO2016128948A1 (en) 2016-08-18
CA2976030C (en) 2023-09-26
MX379057B (es) 2025-03-10
CR20170371A (es) 2018-01-22
PH12017501427A1 (en) 2018-01-15
SG11201706510YA (en) 2017-09-28
WO2016128949A1 (en) 2016-08-18
EA201791667A1 (ru) 2018-02-28
US20210053996A1 (en) 2021-02-25
CN107531730A (zh) 2018-01-02
JP2018506540A (ja) 2018-03-08
CY1123687T1 (el) 2022-03-24
MX2017010413A (es) 2018-05-11
UA120527C2 (uk) 2019-12-26
RS60885B1 (sr) 2020-11-30
SG11201706511TA (en) 2017-09-28
ES2821951T3 (es) 2021-04-28
MX2017010414A (es) 2018-05-11
KR20170117156A (ko) 2017-10-20
BR112017017211B1 (pt) 2023-04-25
EP3256479A1 (en) 2017-12-20
PH12017501428A1 (en) 2018-01-15
HRP20201597T1 (hr) 2020-12-25
US11214582B2 (en) 2022-01-04
EA036516B1 (ru) 2020-11-18
EA201791671A1 (ru) 2018-02-28
EP3256479B1 (en) 2020-07-29
DK3256479T3 (da) 2020-11-02
NZ734379A (en) 2023-06-30
CA2976030A1 (en) 2016-08-18
EP3256480A1 (en) 2017-12-20
MY194004A (en) 2022-11-07
TWI730953B (zh) 2021-06-21
HUE051113T2 (hu) 2021-01-28
AU2020256369A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
CO2017008809A2 (es) Compuestos de benzoxaborol y uso de los mismos
CR20160064A (es) Compuestos de benzoxaborol tricíclicos y usos de los mismos
AR089671A1 (es) 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CU20180144A7 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
PE20211782A1 (es) Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos
CO6630154A2 (es) Ciertas amino-piridazinas, composiciones de las mismas y métodos de uso de los mimos
AR103251A1 (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
AR091285A1 (es) Inhibidores de bromodominio y sus usos
CU20170105A7 (es) Derivados de nucleosidos sustituidos útiles como agentes antineoplásicos
CU20170164A7 (es) Compuestos n-tieno (2,3-d)pirimidinil-d-fenilalanina, método para preparar los mismos y composiciones farmacéuticas que los contienen
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
UY35641A (es) PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO)
ECSP14004812A (es) Triazolopiridinas sustituidas
UY34388A (es) &#34;5,7-IMIDAZO[1,2-c]PIRIMIDINAS SUSTITUIDAS&#34;
ECSP13012596A (es) Proceso de elaboración para derivados de pirimidina
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
PE20170703A1 (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y metodos de uso de los mismos
UY36651A (es) Compuestos antiestrogénicos
CU20160148A7 (es) Compuestos de azol sustituidos con amida como inhibidores de tnks1 y/o tnks2
AR102544A1 (es) Compuestos derivados de dihidrohidantoína como herbicidas
CO2022006942A2 (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria
AR093168A1 (es) COMPUESTOS DE OXAZOLIDINONA COMO INHIBIDORES DEL CANAL KCa3.1
UY36662A (es) Compuestos de benzoxaborol y uso de los mismos